FDA Approves Genentech’s Cancer Immunotherapy TECENTRIQ (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer

Posted by ALCF Staff on October 18th, 2016

Genentech’s PDL1 drug approved in the second line setting for people “with metastatic non-small cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving atezolizumab.”


Leave a Reply: